Lion Biotechnologies (IOVA) Receiving Somewhat Positive Press Coverage, Analysis Finds
News coverage about Lion Biotechnologies (NASDAQ:IOVA) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lion Biotechnologies earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.4924235098611 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting (finance.yahoo.com)
- Iovance: Earnings Review, Analysts Target Price and Upcoming SITC Data Release (finance.yahoo.com)
- Lion Biotechnologies, Inc. (IOVA) Forecasted to Earn FY2017 Earnings of ($1.23) Per Share (americanbankingnews.com)
- Lion Biotechnologies, Inc. (IOVA) Forecasted to Post FY2017 Earnings of ($1.38) Per Share (americanbankingnews.com)
Several equities analysts recently commented on IOVA shares. Zacks Investment Research raised Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Tuesday, July 18th. Oppenheimer Holdings, Inc. started coverage on Lion Biotechnologies in a research report on Friday, August 4th. They set an “outperform” rating and a $13.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Lion Biotechnologies in a research report on Wednesday, August 16th. Cowen and Company reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Wednesday, August 16th. Finally, Chardan Capital reissued a “buy” rating and set a $20.00 price target on shares of Lion Biotechnologies in a research report on Friday, September 1st. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Lion Biotechnologies has an average rating of “Buy” and a consensus price target of $14.53.
Lion Biotechnologies (NASDAQ:IOVA) opened at $8.05 on Friday. Lion Biotechnologies has a 52-week low of $4.45 and a 52-week high of $8.60.
Lion Biotechnologies (NASDAQ:IOVA) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). equities analysts forecast that Lion Biotechnologies will post -1.37 EPS for the current fiscal year.
About Lion Biotechnologies
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.